Previous 10 | Next 10 |
2023-04-06 12:35:54 ET FDA’s accelerated drug approval program came under scrutiny on Thursday after the agency withdrew its approval for Makena, a drug first cleared the regulatory hurdle more than a decade ago to prevent preterm birth in women. The FDA approved Makena in 2011 u...
2023-04-06 11:51:32 ET Summary Ionis and Biogen have been partnering on antisense drug development for a decade. The two companies won approval for $1.8bn (in 2022) Spinraza, indicated for Spinal Muscular Atrophy. Tofersen, indicated for ALS, is not expected to generate peak r...
2023-04-06 06:28:02 ET Summary Biogen and Eisa compared the effects of their drug Leqembi against the combined placebo decline rather than against the different rates of decline for APOE4 carriers and non-carriers. This made Leqembi look more effective for non-carriers than it act...
2023-04-05 13:10:09 ET Summary The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. In addition, we will take a look into 2 companies more in-depth, which we found particularly intere...
2023-04-05 03:09:19 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-04-04 12:20:43 ET Adam Keeney is joining Biogen as head of corporate development, beginning April 17. He was formerly the CEO of clinical stage biotech NodThera. Keeney also had stints at Sanofi ( SNY ) and Johnson & Johnson ( JNJ ). He also holds a Ph.D...
CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen’s Executive Committee reporti...
2023-04-04 06:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-03 07:05:32 ET The U.S. National Institute on Aging (NIA) is funding an up to $300M project to create a research database for Alzheimer's disease (AD) which can track Americans' health for many years and help researchers to get insights on AD, Reuters reported. The NIA plan...
ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS PR Newswire TOKYO and CAMBRIDGE, Mass. , March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eis...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...